Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case–control study

Lipids in Health and Disease

Research

Puhong Zhang¹  Jialin Gao²  Yao Zhang³  Lizhuo Wang³  Chun Pu⁴  Lizhu Huang⁴  Gang Feng⁴  Qingsong Tao⁴ 

[1] Anhui Province Key Laboratory of Biological Macro-molecules Research (Wannan Medical College), Wuhu, China;Anhui Province Key Laboratory of Biological Macro-molecules Research (Wannan Medical College), Wuhu, China;Department of Endocrinology and Genetic Metabolism, Yijishan Hospital of Wannan Medical College, Wuhu, China;Department of Biochemistry and Molecular Biology, Wannan Medical College, 22 West Wenchang Road, 241002, Wuhu, People’s Republic of China;Anhui Province Key Laboratory of Biological Macro-molecules Research (Wannan Medical College), Wuhu, China;Department of Clinical Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, China;

关键词: Apolipoproteins;    Diabetes;    HDL;    Lipids;    Dyslipidaemia;   

DOI  :  10.1186/s12944-016-0325-1

 received in 2016-02-26, accepted in 2016-09-03,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundApolipoprotein M (apoM) is mainly enriched in high-density lipoprotein (HDL) cholesterol and is slightly present in low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol. apoM is involved in HDL formation and HDL-mediated reverse cholesterol transport. apoM is also associated with hyperlipidaemia and type 2 diabetes mellitus (T2DM). Significantly high plasma apoM levels are detected in hyperlipidaemia mice with a defective LDL receptor. By contrast, low plasma apoM levels are observed in patients with T2DM, which is often accompanied with hyperlipidaemia. However, the underlying mechanism of this condition is poorly understood. This research aims to examine the changes in apoM levels in patients with hyperlipidaemia and to determine the effects of hyperlipidaemia on plasma apoM levels in patients with T2DM.MethodsThis study included patients with hyperlipidaemia (n = 79), patients with T2DM but without hyperlipidaemia (n = 125), patients with T2DM and hyperlipidaemia (n = 98), and healthy controls (n = 105). Their plasma apoM concentrations were measured with enzyme-linked immunosorbent assay.ResultsThe average plasma apoM concentrations were 18 % higher in the hyperlipidaemia group (26.63 ± 10.35 ng/μL) than in the healthy controls (22.61 ± 10.81 ng/μL, P <0.01). The plasma apoM concentrations were lower in the T2DM without hyperlipidaemia group (18.54 ± 10.33 ng/μL, P <0.01) and the T2DM with hyperlipidaemia group (19.83 ± 7.41 ng/μL, P <0.05) than in the healthy controls. Similar to apoA-I (1.29 ± 0.33 g/L vs. 1.28 ± 0.31 g/L, P >0.05), the plasma apoM concentrations in the T2DM with hyperlipidaemia group did not significantly differ from those in the T2DM without hyperlipidaemia group (P >0.05). Multivariate linear regression analysis showed that hyperlipidaemia (β = 5.18, P = 0.007) is an independent promoting factor of plasma apoM levels and diabetes (β = −3.09, P = 0.005) is an inhibiting factor of plasma apoM levels.ConclusionPlasma apoM concentrations are higher in patients with hyperlipidaemia than in healthy controls. Low plasma apoM levels in patients with T2DM are likely caused by diabetes but are not induced by hyperlipidaemia.

【 授权许可】

CC BY   
© The Author(s). 2016